ライフサイエンスコーパス: oxyntomodulin

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 eceptor activation of the endogenous peptide oxyntomodulin.

2 characterized to induce biased signaling by oxyntomodulin.

3 3-36) or oxyntomodulin or combined PYY(3-36)/oxyntomodulin.

4 nously via minipumps with either saline, rat oxyntomodulin (0.47 nmol x kg(-1) x h[-1]), or glucagon

5 The hypothesis that infusions of oxyntomodulin, a bioactive form of enteroglucagon, would

6 -36) (PYY(3-36)), a Y2 receptor agonist, and oxyntomodulin, a glucagon-like peptide 1 (GLP-1) recepto

7 We show that oxyntomodulin, a peptide with potential to treat obesity

8 Met-303 was more important for exendin-4 and oxyntomodulin action than those of GLP-1 peptides.

9 ion binding studies were used to investigate oxyntomodulin activity on the GLP-1 receptor in the pres

10 In contrast, oxyntomodulin and glucagon significantly stimulated tota

11 on other gut hormones such as GIP, ghrelin, oxyntomodulin and peptide YY.

12 Oxyntomodulin and the growth hormone-(1-43) fragment wer

13 endogenous ligands glucagon-like peptide-1, oxyntomodulin, and the clinically used mimetic exendin-4

14 aling of the peptide mimetics, exendin-4 and oxyntomodulin, as well as small molecule allosteric agon

15 BETP increased oxyntomodulin binding affinity for the GLP-1 receptor an

16 greatly prolonged exposure, with a constant oxyntomodulin bioactivity detectable in serum for at lea

17 The anorectic effects of PYY(3-36) and oxyntomodulin can be additive in overweight and obese hu

18 ether the anorectic effects of PYY(3-36) and oxyntomodulin can be additive.

19 granin A (CgA), serotonin, peptide YY (PYY), oxyntomodulin (enteroglucagon), pancreatic polypeptide,

20 ation of glicentin as well as low amounts of oxyntomodulin, GLP-1, truncated GLP-1, and N-terminally

21 Oxyntomodulin has been shown to reduce weight and food i

22 ecause of the unique metabolic properties of oxyntomodulin, identifying molecules that enhance its ac

23 e results support a new, specific action for oxyntomodulin in intestinal adaptation as a glucose upta

24 avenous glucose tolerance test characterized oxyntomodulin-induced insulin secretion in animals admin

25 In addition, oxyntomodulin-induced insulin secretion was enhanced in

26 important for GLP-1- and exendin-4-, but not oxyntomodulin-mediated cAMP formation and also ERK1/2 ph

27 affinity for the GLP-1 receptor and enhanced oxyntomodulin-mediated GLP-1 receptor signaling as measu

28 Oxyntomodulin most potently enhanced glucose uptake in t

29 intravenous infusions of either PYY(3-36) or oxyntomodulin or combined PYY(3-36)/oxyntomodulin.

30 peptide-1 (GLP-1), cholecystokinin (CCK) and oxyntomodulin (OXM) as treatments for obesity-diabetes.

31 on-like peptide (GLP-1), glucagon (GCG), and oxyntomodulin (OXM) directly into the brain.

32 Oxyntomodulin (OXM) is a glucagon-like peptide 1 (GLP-1)

33 Application of this strategy to oxyntomodulin (OXM), a peptide hormone that stimulates i

34 food-driven liver clock resetting involving oxyntomodulin (OXM).

35 ulating peptide YY, glucagon-like peptide 1, oxyntomodulin, pancreatic polypeptide, leptin, and adipo

36 ake during coadministration of PYY(3-36) and oxyntomodulin was reduced by 42.7% in comparison with th

37 erum for at least 5 days as compared to free oxyntomodulin which is undetectable after only 4 h.

38 ing the low-affinity GLP-1 receptor agonist, oxyntomodulin, would improve the insulin secretory prope

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。